March 30, 2026
1 min read

FDA extends review of Orca Bio’s novel cell therapy for blood cancers

The FDA has delayed its target decision date for Orca Bio’s blood cancer cell therapy candidate Orca-T by three months to July 6 after the company submitted additional CMC-related data.

Leave a Reply

Your email address will not be published.

Previous Story

Food as Medicine: How Trinity Health Is Advancing Health Through Nutrition

Next Story

Secretary Kennedy Celebrates Hospital Nutrition Commitments, Florida Farm Partnership During ‘Take Back Your Health’ Tour in Miami

Previous Story

Food as Medicine: How Trinity Health Is Advancing Health Through Nutrition

Next Story

Secretary Kennedy Celebrates Hospital Nutrition Commitments, Florida Farm Partnership During ‘Take Back Your Health’ Tour in Miami

Latest from Blog

ROFI Drives New Approach to Crop Nutrition

With input costs continuing to pressure farm budgets, some growers are making difficult decisions to reduce fertilizer application rates. While that strategy may ease upfront expenses, it is also accelerating a broader
Go toTop